 [1m([0morchestrator-myocardial infarction-ENALAPRIL MALEATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ENALAPRIL MALEATE increase or decrease the risk of [0m
[34mmyocardial infarction?[0m
 [1m([0morchestrator-myocardial infarction-ENALAPRIL MALEATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ENALAPRIL MALEATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-myocardial infarction-ENALAPRIL MALEATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"ENALAPRIL MALEATE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-ENALAPRIL MALEATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mENALAPRIL MALEATE[0m
 [1m([0morchestrator-myocardial infarction-ENALAPRIL MALEATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ENALAPRIL MALEATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-ENALAPRIL MALEATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mENALAPRIL MALEATE[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"ENALAPRIL MALEATE"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ENALAPRIL MALEATE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: ENALAPRIL MALEATE: openfda: generic_name         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: openfda: brand_name         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: openfda: product_type         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: clinical_pharmacology: CLINICAL PHARMACOLOGY Mechanism of Action Enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme [0m[1;31m([0m[31mACE[0m[1;31m)[0m[31m in human subjects [0m
[31mand animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the [0m
[31madrenal cortex. The beneficial effects of enalapril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results[0m
[31min decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Although the latter decrease is small, it results in small increases of serum [0m
[31mpotassium. ENALAPRIL MALEATE: mechanism_of_action: In hypertensive patients treated with enalapril maleate alone for up to [0m[1;31m48[0m[31m weeks, mean increases in serum potassium of approximately [0m[1;31m0.2[0m[31m mEq/L were [0m
[31mobserved. In patients treated with enalapril maleate plus a thiazide diuretic, there was essentially no change in serum potassium [0m[1;31m([0m[31msee PRECAUTIONS [0m[1;31m)[0m[31m. Removal of angiotensin II negative feedback on [0m
[31mrenin secretion leads to increased plasma renin activity. ACE is identical to kininase, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasodepressor peptide, play[0m
[31ma role in the therapeutic effects of enalapril maleate remains to be elucidated. ENALAPRIL MALEATE: clinical_pharmacology: While the mechanism through which enalapril maleate lowers blood pressure is [0m
[31mbelieved to be primarily suppression of the renin-angiotensin-aldosterone system, enalapril maleate is antihypertensive even in patients with low-renin hypertension. Although enalapril maleate was [0m
[31mantihypertensive in all races studied, black hypertensive patients [0m[1;31m([0m[31musually a low-renin hypertensive population[0m[1;31m)[0m[31m had a smaller average response to enalapril monotherapy than non-black patients. [0m
[31mPharmacokinetics and Metabolism Following oral administration of enalapril maleate, peak serum concentrations of enalapril occur within about one hour. Based on urinary recovery, the extent of [0m
[31mabsorption of enalapril is approximately [0m[1;31m60[0m[31m percent. Enalapril absorption is not influenced by the presence of food in the gastrointestinal tract. ENALAPRIL MALEATE: clinical_pharmacology: Following [0m
[31mabsorption, enalapril is hydrolyzed to enalaprilat, which is a more potent angiotensin-converting enzyme inhibitor than enalapril; enalaprilat is poorly absorbed when administered orally. Peak serum [0m
[31mconcentrations of enalaprilat occur three to four hours after an oral dose of enalapril maleate. Excretion of enalapril maleate is primarily renal. Approximately [0m[1;31m94[0m[31m percent of the dose is recovered in[0m
[31mthe urine and feces as enalaprilat or enalapril. The principal components in urine are enalaprilat, accounting for about [0m[1;31m40[0m[31m percent of the dose, and intact enalapril. There is no evidence of [0m
[31mmetabolites of enalapril, other than enalaprilat. The serum concentration profile of enalaprilat exhibits a prolonged terminal phase, apparently representing a small fraction of the administered dose [0m
[31mthat has been bound to ACE. ENALAPRIL MALEATE: clinical_pharmacology: The amount bound does not increase with dose, indicating a saturable site of binding. The effective half-life for accumulation of [0m
[31menalaprilat following multiple doses of enalapril maleate is [0m[1;31m11[0m[31m hours. The disposition of enalapril and enalaprilat in patients with renal insufficiency is similar to that in patients with normal [0m
[31mrenal function until the glomerular filtration rate is [0m[1;31m30[0m[31m mL/min or less. With glomerular filtration rate â‰¤ [0m[1;31m30[0m[31m mL/min, peak and trough enalaprilat levels increase, time to peak concentration increases[0m
[31mand time to steady state may be delayed. The effective half-life of enalaprilat following multiple doses of enalapril maleate is prolonged at this level of renal insufficiency [0m[1;31m([0m[31msee DOSAGE AND [0m
[31mADMINISTRATION [0m[1;31m)[0m[31m. Enalaprilat is dialyzable at the rate of [0m[1;31m62[0m[31m mL/min. ENALAPRIL MALEATE: mechanism_of_action: Mechanism of Action Enalapril, after hydrolysis to enalaprilat, inhibits [0m
[31mangiotensin-converting enzyme [0m[1;31m([0m[31mACE[0m[1;31m)[0m[31m in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. [0m
[31mAngiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of enalapril in hypertension and heart failure appear to result primarily from suppression of the [0m
[31mrenin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Although the [0m
[31mlatter decrease is small, it results in small increases of serum potassium. ENALAPRIL MALEATE: mechanism_of_action: While the mechanism through which enalapril maleate lowers blood pressure is [0m
[31mbelieved to be primarily suppression of the renin-angiotensin-aldosterone system, enalapril maleate is antihypertensive even in patients with low-renin hypertension. Although enalapril maleate was [0m
[31mantihypertensive in all races studied, black hypertensive patients [0m[1;31m([0m[31musually a low-renin hypertensive population[0m[1;31m)[0m[31m had a smaller average response to enalapril monotherapy than non-black patients.       [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: indications_and_usage: INDICATIONS AND USAGE Hypertension Enalapril maleate tablets, USP are indicated for the treatment of hypertension. Enalapril maleate tablets, USP are[0m
[31meffective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately [0m
[31madditive. Heart Failure Enalapril maleate tablets, USP are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients [0m
[31menalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization [0m[1;31m([0m[31msee CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of [0m
[31msurvival trials[0m[1;31m)[0m[31m. ENALAPRIL MALEATE: indications_and_usage: Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction [0m[1;31m([0m[31mejection fraction [0m
[31mâ‰¤[0m[1;31m35[0m[31m percent[0m[1;31m)[0m[31m, enalapril maleate tablets, USP decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure [0m[1;31m([0m[31msee CLINICAL PHARMACOLOGY, Heart[0m
[31mFailure, Mortality Trials for details and limitations of survival trials[0m[1;31m)[0m[31m. In using enalapril maleate, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, [0m
[31mcaptopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not [0m
[31mhave a similar risk [0m[1;31m([0m[31msee WARNINGS , Neutropenia/Agranulocytosis [0m[1;31m)[0m[31m. ENALAPRIL MALEATE: indications_and_usage: In considering use of enalapril maleate, it should be noted that in controlled clinical [0m
[31mtrials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been [0m
[31mreported to have a higher incidence of angioedema compared to non-blacks [0m[1;31m([0m[31msee WARNINGS, Head and Neck Angioedema [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: warnings: WARNINGS Anaphylactoid and Possibly Related Reactions Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and [0m
[31mpolypeptides, including endogenous bradykinin, patients receiving ACE inhibitors [0m[1;31m([0m[31mincluding enalapril maleate[0m[1;31m)[0m[31m may be subject to a variety of adverse reactions, some of them serious. Head and Neck [0m
[31mAngioedema Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported in patients treated with angiotensin-converting enzyme inhibitors, including enalapril maleate. [0m
[31mThis may occur at any time during treatment. In such cases enalapril maleate should be promptly discontinued and appropriate therapy and monitoring should be provided until complete and sustained [0m
[31mresolution of signs and symptoms has occurred. ENALAPRIL MALEATE: warnings: In instances where swelling has been confined to the face and lips the condition has generally resolved without treatment, [0m
[31malthough antihistamines have been useful in relieving symptoms. Angioedema associated with laryngeal edema may be fatal. Where there is involvement of the tongue, glottis or larynx, likely to cause [0m
[31mairway obstruction, appropriate therapy, e.g., subcutaneous epinephrine solution [0m[1;31m1:1000[0m[31m [0m[1;31m([0m[1;31m0.3[0m[31m mL to [0m[1;31m0.5[0m[31m mL[0m[1;31m)[0m[31m and/or measures necessary to ensure a patent airway, should be promptly provided [0m[1;31m([0m[31msee ADVERSE[0m
[31mREACTIONS [0m[1;31m)[0m[31m. Patients receiving coadministration of ACE inhibitor and mTOR [0m[1;31m([0m[31mmammalian target of rapamycin[0m[1;31m)[0m[31m inhibitor [0m[1;31m([0m[31me.g., temsirolimus, sirolimus, everolimus[0m[1;31m)[0m[31m therapy or a neprilysin inhibitor may [0m
[31mbe at increased risk for angioedema [0m[1;31m([0m[31msee PRECAUTIONS [0m[1;31m)[0m[31m. ENALAPRIL MALEATE: warnings: Intestinal Angioedema Intestinal angioedema has been reported in patients treated with ACE inhibitors. These [0m
[31mpatients presented with abdominal pain [0m[1;31m([0m[31mwith or without nausea or vomiting[0m[1;31m)[0m[31m; in some cases there was no prior history of facial angioedema and C1 esterase levels were normal. The angioedema was [0m
[31mdiagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be included in the differential [0m
[31mdiagnosis of patients on ACE inhibitors presenting with abdominal pain. Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving [0m
[31man ACE inhibitor [0m[1;31m([0m[31msee INDICATIONS AND USAGE and CONTRAINDICATIONS [0m[1;31m)[0m[31m. Anaphylactoid Reactions During Desensitization Two patients undergoing desensitizing treatment with hymenoptera venom while [0m
[31mreceiving ACE inhibitors sustained life-threatening anaphylactoid reactions.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: adverse_reactions: Pediatric Patients The adverse experience profile for pediatric patients appears to be similar to that seen in adult patients. Clinical Laboratory Test [0m
[31mFindings Serum Electrolytes Hyperkalemia [0m[1;31m([0m[31msee PRECAUTIONS, Hyperkalemia [0m[1;31m)[0m[31m, hyponatremia. Creatinine, Blood Urea Nitrogen In controlled clinical trials minor increases in blood urea nitrogen and serum [0m
[31mcreatinine, reversible upon discontinuation of therapy, were observed in about [0m[1;31m0.2[0m[31m percent of patients with essential hypertension treated with enalapril maleate alone. Increases are more likely to [0m
[31moccur in patients receiving concomitant diuretics or in patients with renal artery stenosis [0m[1;31m([0m[31msee PRECAUTIONS, Impaired Renal Function [0m[1;31m)[0m[31m. ENALAPRIL MALEATE: adverse_reactions: In patients with heart [0m
[31mfailure who were also receiving diuretics with or without digitalis, increases in blood urea nitrogen or serum creatinine, usually reversible upon discontinuation of enalapril maleate and/or other [0m
[31mconcomitant diuretic therapy, were observed in about [0m[1;31m11[0m[31m percent of patients. Increases in blood urea nitrogen or creatinine were a cause for discontinuation in [0m[1;31m1.2[0m[31m percent of patients. Hematology [0m
[31mSmall decreases in hemoglobin and hematocrit [0m[1;31m([0m[31mmean decreases of approximately [0m[1;31m0.3[0m[31m g percent and [0m[1;31m1[0m[31m vol percent, respectively[0m[1;31m)[0m[31m occur frequently in either hypertension or congestive heart failure [0m
[31mpatients treated with enalapril maleate but are rarely of clinical importance unless another cause of anemia coexists. In clinical trials, less than [0m[1;31m0.1[0m[31m percent of patients discontinued therapy due to[0m
[31manemia. ENALAPRIL MALEATE: adverse_reactions: Hemolytic anemia, including cases of hemolysis in patients with G6PD deficiency, has been reported; a causal relationship to enalapril cannot be excluded.[0m
[31mLiver Function Tests Elevations of liver enzymes and/or serum bilirubin have occurred [0m[1;31m([0m[31msee WARNINGS, Hepatic Failure [0m[1;31m)[0m[31m. To report SUSPECTED ADVERSE REACTIONS, contact Northstar Rx LLC at [0m
[1;31m1[0m[31m-[0m[1;31m800[0m[31m-[0m[1;31m206[0m[31m-[0m[1;31m7821[0m[31m or FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m or www.fda.gov/medwatch.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: adverse_reactions: [0m[1;31m6[0m[31m Headache [0m[1;31m1.8[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m0.9[0m[31m Vertigo [0m[1;31m1.6[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m1.2[0m[31m Respiratory Cough [0m[1;31m2.2[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m [0m[1;31m0.6[0m[31m Bronchitis [0m[1;31m1.3[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m [0m[1;31m0.9[0m[31m Dyspnea [0m[1;31m1.3[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m0.4[0m[31m Pneumonia [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m [0m[1;31m2.4[0m[31m Skin Rash [0m
[1;31m1.3[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m [0m[1;31m2.4[0m[31m Urogenital Urinary Tract Infection [0m[1;31m1.3[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m [0m[1;31m2.4[0m[31m Other serious clinical adverse experiences occurring since the drug was marketed or adverse experiences occurring in [0m[1;31m0.5[0m[31m to [0m[1;31m1[0m[31m percent of [0m
[31mpatients with hypertension or heart failure in clinical trials are listed below and, within each category, are in order of decreasing severity. Body As A Whole Anaphylactoid reactions [0m[1;31m([0m[31msee WARNINGS, [0m
[31mAnaphylactoid and Possibly Related Reactions [0m[1;31m)[0m[31m. ENALAPRIL MALEATE: adverse_reactions: Cardiovascular Cardiac arrest; myocardial infarction or cerebrovascular accident, possibly secondary to excessive [0m
[31mhypotension in high risk patients [0m[1;31m([0m[31msee WARNINGS, Hypotension [0m[1;31m)[0m[31m; pulmonary embolism and infarction; pulmonary edema; rhythm disturbances including atrial tachycardia and bradycardia; atrial [0m
[31mfibrillation; palpitation, Raynaud's phenomenon. Digestive Ileus, pancreatitis, hepatic failure, hepatitis [0m[1;31m([0m[31mhepatocellular [0m[31m or cholestatic jaundice[0m[1;31m)[0m[31m [0m[1;31m([0m[31msee WARNINGS, Hepatic Failure [0m[1;31m)[0m[31m, melena, anorexia,[0m
[31mdyspepsia, constipation, glossitis, stomatitis, dry mouth. Hematologic Rare cases of neutropenia, thrombocytopenia and bone marrow depression. Musculoskeletal Muscle cramps. ENALAPRIL MALEATE: [0m
[31madverse_reactions: Nervous/Psychiatric Depression, confusion, ataxia, somnolence, insomnia, nervousness, peripheral neuropathy [0m[1;31m([0m[31me.g., paresthesia, dysesthesia[0m[1;31m)[0m[31m, dream abnormality. Respiratory [0m
[31mBronchospasm, rhinorrhea, sore throat and hoarseness, asthma, upper respiratory infection, pulmonary infiltrates, eosinophilic pneumonitis. Skin Exfoliative dermatitis, toxic epidermal necrolysis, [0m
[31mStevens-Johnson syndrome, pemphigus, herpes zoster, erythema multiforme, urticaria, pruritus, alopecia, flushing, diaphoresis, photosensitivity. Special Senses Blurred vision, taste alteration, [0m
[31manosmia, tinnitus, conjunctivitis, dry eyes, tearing. ENALAPRIL MALEATE: adverse_reactions: Urogenital Renal failure, oliguria, renal dysfunction [0m[1;31m([0m[31msee PRECAUTIONS and DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m, [0m
[31mflank pain, gynecomastia, impotence. Miscellaneous A symptom complex has been reported which may include some or all of the following: a positive ANA, an elevated erythrocyte sedimentation rate, [0m
[31marthralgia/arthritis, myalgia/myositis, fever, serositis, vasculitis, leukocytosis, eosinophilia, photosensitivity, rash and other dermatologic manifestations. Angioedema Angioedema has been reported [0m
[31min patients receiving enalapril maleate, with an incidence higher in black than in non-black patients. Angioedema associated with laryngeal edema may be fatal. ENALAPRIL MALEATE: adverse_reactions: If[0m
[31mangioedema of the face, extremities, lips, tongue, glottis and/or larynx occurs, treatment with enalapril maleate should be discontinued and appropriate therapy instituted immediately [0m[1;31m([0m[31msee WARNINGS, [0m
[31mHead and Neck Angioedema [0m[1;31m)[0m[31m. Hypotension In the hypertensive patients, hypotension occurred in [0m[1;31m0.9[0m[31m percent and syncope occurred in [0m[1;31m0.5[0m[31m percent of patients following the initial dose or during extended [0m
[31mtherapy. Hypotension or syncope was a cause for discontinuation of therapy in [0m[1;31m0.1[0m[31m percent of hypertensive patients. In heart failure patients, hypotension occurred in [0m[1;31m6.7[0m[31m percent and syncope occurred [0m
[31min [0m[1;31m2.2[0m[31m percent of patients. Hypotension or syncope was a cause for discontinuation of therapy in [0m[1;31m1.9[0m[31m percent of patients with heart failure [0m[1;31m([0m[31msee WARNINGS, Hypotension [0m[1;31m)[0m[31m. Cough See PRECAUTIONS, Cough .[0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: dosage_and_administration: For patients with creatinine clearance less than or equal to [0m[1;31m30[0m[31m mL/min [0m[1;31m([0m[31mserum creatinine more than or equal to [0m[1;31m3[0m[31m mg/dL[0m[1;31m)[0m[31m, the first dose is [0m[1;31m2.5[0m[31m mg[0m
[31monce daily. The dosage may be titrated upward until blood pressure is controlled or to a maximum of [0m[1;31m40[0m[31m mg daily. Renal Status Creatinine Clearance mL/min Initial Dose mg/day Normal Renal Function >[0m[1;31m80[0m[31m [0m
[31mmL/min [0m[1;31m5[0m[31m mg Mild Impairment â‰¤[0m[1;31m80[0m[31m >[0m[1;31m30[0m[31m mL/min [0m[1;31m5[0m[31m mg Moderate to Severe Impairment â‰¤[0m[1;31m30[0m[31m mL/min [0m[1;31m2.5[0m[31m mg Dialysis Patients See WARNINGS, Anaphylactoid Reactions During Membrane Exposure. [0m[1;31m2.5[0m[31m mg on dialysis [0m
[31mdays Dosage on nondialysis days should be adjusted depending on the blood pressure response. Heart Failure Enalapril maleate tablets, USP are indicated for the treatment of symptomatic heart failure, [0m
[31musually in combination with diuretics and digitalis. ENALAPRIL MALEATE: dosage_and_administration: In the placebo-controlled studies that demonstrated improved survival, patients were titrated as [0m
[31mtolerated up to [0m[1;31m40[0m[31m mg, administered in two divided doses. The recommended initial dose is [0m[1;31m2.5[0m[31m mg. The recommended dosing range is [0m[1;31m2.5[0m[31m to [0m[1;31m20[0m[31m mg given twice a day. Doses should be titrated upward, as [0m
[31mtolerated, over a period of a few days or weeks. The maximum daily dose administered in clinical trials was [0m[1;31m40[0m[31m mg in divided doses. After the initial dose of enalapril maleate tablets USP, the patient[0m
[31mshould be observed under medical supervision for at least two hours and until blood pressure has stabilized for at least an additional hour [0m[1;31m([0m[31msee WARNINGS and PRECAUTIONS, Drug Interactions [0m[1;31m)[0m[31m. If [0m
[31mpossible, the dose of any concomitant diuretic should be reduced which may diminish the likelihood of hypotension. ENALAPRIL MALEATE: dosage_and_administration: The appearance of hypotension after the[0m
[31minitial dose of enalapril maleate tablets, USP does not preclude subsequent careful dose titration with the drug, following effective management of the hypotension. Asymptomatic Left Ventricular [0m
[31mDysfunction In the trial that demonstrated efficacy, patients were started on [0m[1;31m2.5[0m[31m mg twice daily and were titrated as tolerated to the targeted daily dose of [0m[1;31m20[0m[31m mg [0m[1;31m([0m[31min divided doses[0m[1;31m)[0m[31m. After the [0m
[31minitial dose of enalapril maleate tablets USP, the patient should be observed under medical supervision for at least two hours and until blood pressure has stabilized for at least an additional hour [0m
[1;31m([0m[31msee WARNINGS and PRECAUTIONS, Drug Interactions [0m[1;31m)[0m[31m. If possible, the dose of any concomitant diuretic should be reduced which may diminish the likelihood of hypotension. ENALAPRIL MALEATE: [0m
[31mdosage_and_administration: The appearance of hypotension after the initial dose of enalapril maleate tablets, USP does not preclude subsequent careful dose titration with the drug, following effective[0m
[31mmanagement of the hypotension. Dosage Adjustment in Patients with Heart Failure and Renal Impairment or Hyponatremia In patients with heart failure who have hyponatremia [0m[1;31m([0m[31mserum sodium less than [0m[1;31m130[0m[31m [0m
[31mmEq/L[0m[1;31m)[0m[31m or with serum creatinine greater than [0m[1;31m1.6[0m[31m mg/dL, therapy should be initiated at [0m[1;31m2.5[0m[31m mg daily under close medical supervision [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION, Heart Failure , WARNINGS and [0m
[31mPRECAUTIONS, Drug Interactions [0m[1;31m)[0m[31m. The dose may be increased to [0m[1;31m2.5[0m[31m mg b.i.d., then [0m[1;31m5[0m[31m mg b.i.d. and higher as needed, usually at intervals of four days or more if at the time of dosage adjustment there[0m
[31mis not excessive hypotension or significant deterioration of renal function. ENALAPRIL MALEATE: dosage_and_administration: The maximum daily dose is [0m[1;31m40[0m[31m mg. Pediatric Hypertensive Patients The usual [0m
[31mrecommended starting dose is [0m[1;31m0.08[0m[31m mg/kg [0m[1;31m([0m[31mup to [0m[1;31m5[0m[31m mg[0m[1;31m)[0m[31m once daily. Dosage should be adjusted according to blood pressure response. Doses above [0m[1;31m0.58[0m[31m mg/kg [0m[1;31m([0m[31mor in excess of [0m[1;31m40[0m[31m mg[0m[1;31m)[0m[31m have not been studied in[0m
[31mpediatric patients [0m[1;31m([0m[31msee CLINICAL PHARMACOLOGY, Clinical Pharmacology in Pediatric Patients [0m[1;31m)[0m[31m. Enalapril maleate tablets, USP are not recommended in neonates and in pediatric patients with glomerular [0m
[31mfiltration rate less than [0m[1;31m30[0m[31m mL/min/[0m[1;31m1.73[0m[31m m [0m[1;31m2[0m[31m , as no data are available.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: clinical_pharmacology: SURVIVAL [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m Six Months One Year Enalapril Maleate [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m127[0m[1;31m)[0m[31m [0m[1;31m74[0m[31m [0m[1;31m64[0m[31m Placebo [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m126[0m[1;31m)[0m[31m [0m[1;31m56[0m[31m [0m[1;31m48[0m[31m In both CONSENSUS and SOLVD-Treatment trials, patients were [0m
[31malso usually receiving digitalis, diuretics or both. Clinical Pharmacology in Pediatric Patients A multiple dose pharmacokinetic study was conducted in [0m[1;31m40[0m[31m hypertensive male and female pediatric [0m
[31mpatients aged [0m[1;31m2[0m[31m months to â‰¤[0m[1;31m16[0m[31m years following daily oral administration of [0m[1;31m0.07[0m[31m to [0m[1;31m0.14[0m[31m mg/kg enalapril maleate. At steady state, the mean effective half-life for accumulation of enalaprilat was [0m[1;31m14[0m[31m [0m
[31mhours, and the mean urinary recovery of total enalapril and enalaprilat in [0m[1;31m24[0m[31m hours was [0m[1;31m68[0m[31m percent of the administered dose. Conversion of enalapril to enalaprilat was in the range of [0m[1;31m63[0m[31m to [0m[1;31m76[0m[31m [0m
[31mpercent. ENALAPRIL MALEATE: clinical_pharmacology: The overall results of this study indicate that the pharmacokinetics of enalapril in hypertensive children aged [0m[1;31m2[0m[31m months to â‰¤[0m[1;31m16[0m[31m years are consistent [0m
[31macross the studied age groups and consistent with pharmacokinetic historic data in healthy adults. In a clinical study involving [0m[1;31m110[0m[31m hypertensive pediatric patients [0m[1;31m6[0m[31m to [0m[1;31m16[0m[31m years of age, patients who [0m
[31mweighed <[0m[1;31m50[0m[31m kg received either [0m[1;31m0.625[0m[31m, [0m[1;31m2.5[0m[31m or [0m[1;31m20[0m[31m mg of enalapril daily and patients who weighed â‰¥[0m[1;31m50[0m[31m kg received either [0m[1;31m1.25[0m[31m, [0m[1;31m5[0m[31m, or [0m[1;31m40[0m[31m mg of enalapril daily. Enalapril administered once daily lowered [0m
[31mtrough blood pressure in a dose-dependent manner. The dose-dependent antihypertensive efficacy of enalapril was consistent across all subgroups [0m[1;31m([0m[31mage, Tanner stage, gender, race[0m[1;31m)[0m[31m. However, the lowest [0m
[31mdoses studied, [0m[1;31m0.625[0m[31m mg and [0m[1;31m1.25[0m[31m mg, corresponding to an average of [0m[1;31m0[0m[31m. ENALAPRIL MALEATE: clinical_pharmacology: [0m[1;31m02[0m[31m mg/kg once daily, did not appear to offer consistent antihypertensive efficacy. In [0m
[31mthis study, enalapril maleate was generally well tolerated. In the above pediatric studies, enalapril maleate was given as tablets of enalapril maleate and for those children and infants who were [0m
[31munable to swallow tablets or who required a lower dose than is available in tablet form, enalapril was administered in a suspension formulation [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION, Preparation of [0m
[31mSuspension [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: spl_product_data_elements: Enalapril Maleate enalapril maleate LACTOSE MONOHYDRATE STARCH, CORN CROSCARMELLOSE SODIUM MAGNESIUM STEARATE SODIUM BICARBONATE FERRIC OXIDE RED[0m
[31mFERROSOFERRIC OXIDE ENALAPRIL MALEATE ENALAPRILAT ANHYDROUS VIOLET ELP;[0m[1;31m20[0m[31m         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: description: DESCRIPTION Enalapril maleate is the maleate salt of enalapril, the ethyl ester of a long-acting angiotensin-converting enzyme inhibitor, enalaprilat. [0m
[31mEnalapril maleate is chemically described as [0m[1;31m([0m[31mS[0m[1;31m)[0m[1;31m-1[0m[31m-[0m[1;31m[[0m[31m N -[0m[1;31m[[0m[1;31m1[0m[31m-[0m[1;31m([0m[31methoxycarbonyl[0m[1;31m)[0m[1;31m-3[0m[31m-phenylpropyl[0m[1;31m][0m[31m-L-alanyl[0m[1;31m][0m[31m-L-proline, [0m[1;31m([0m[31m Z [0m[1;31m)[0m[1;31m-2[0m[31m-butenedioate salt [0m[1;31m([0m[1;31m1:1[0m[1;31m)[0m[31m. Its molecular formula is C [0m[1;31m20[0m[31m H [0m[1;31m28[0m[31m N [0m[1;31m2[0m[31m O [0m[1;31m5[0m[31m âˆ™C [0m[1;31m4[0m[31m H [0m[1;31m4[0m[31m O [0m
[1;31m4[0m[31m, and its structural formula is: Enalapril maleate is a white to off-white, crystalline powder with a molecular weight of [0m[1;31m492.53[0m[31m. It is sparingly soluble in water, soluble in ethanol, and freely [0m
[31msoluble in methanol. ENALAPRIL MALEATE: description: Enalapril is a pro-drug; following oral administration, it is bioactivated by hydrolysis of the ethyl ester to enalaprilat, which is the active [0m
[31mangiotensin-converting enzyme inhibitor. Enalapril maleate is supplied as [0m[1;31m2.5[0m[31m mg, [0m[1;31m5[0m[31m mg, [0m[1;31m10[0m[31m mg, and [0m[1;31m20[0m[31m mg tablets for oral administration. In addition to the active ingredient enalapril maleate, each [0m
[31mtablet contains the following inactive ingredients: corn starch, croscarmellose sodium, lactose monohydrate, magnesium stearate, pregelatinized starch, and sodium bicarbonate. In addition, the [0m[1;31m2.5[0m[31m mg [0m
[31mtablets contain ferric oxide yellow, [0m[1;31m5[0m[31m mg tablets contain ferric oxide red and [0m[1;31m10[0m[31m mg and [0m[1;31m20[0m[31m mg tablets contain ferric oxide red and ferric oxide black. ENALAPRIL MALEATE: description: Structural [0m
[31mformula NS         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: openfda: substance_name         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Enalapril Maleate is an angiotensin-converting enzyme [0m[1;32m([0m[32mACE[0m[1;32m)[0m[32m inhibitor used in the treatment of hypertension and symptomatic congestive heart failure, often in combination with other [0m
[32mmedications such as diuretics and digitalis. It works by inhibiting the conversion of angiotensin I to the vasoconstrictor angiotensin II, leading to decreased vasopressor activity and aldosterone [0m
[32msecretion. This results in the suppression of the renin-angiotensin-aldosterone system, which is the mechanism through which it lowers blood pressure and benefits heart failure patients. Enalapril [0m
[32mMaleate is also indicated for asymptomatic left ventricular dysfunction to decrease the rate of development of overt heart failure and the incidence of hospitalization for heart failure. The drug is [0m
[32mgenerally well tolerated but can cause adverse reactions such as hyperkalemia, hypotension, cough, and angioedema, among others. It is available in tablet form and has a bioactive metabolite called [0m
[32menalaprilat.[0m

[32mSOURCE: ENALAPRIL MALEATE label[0m
[32mEXTRACT_START_END: ENALAPRIL MALEATE: clinical_pharmacology: [0m[32m...[0m[32m in small increases of serum potassium.[0m
*[1m([0morchestrator-myocardial infarction-ENALAPRIL MALEATE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Enalapril Maleate is an angiotensin-converting [0m
[34menzyme [0m[1;34m([0m[34mACE[0m[1;34m)[0m[34m inhibitor used in the treatment of hypertension and symptomatic congestive heart failure, often in combination with other medications such as diuretics and digitalis. It works by [0m
[34minhibiting the conversion of angiotensin I to the vasoconstrictor angiotensin II, leading to decreased vasopressor activity and aldosterone secretion. This results in the suppression of the [0m
[34mrenin-angiotensin-aldosterone system, which is the mechanism through which it lowers blood pressure and benefits heart failure patients. Enalapril Maleate is also indicated for asymptomatic left [0m
[34mventricular dysfunction to decrease the rate of development of overt heart failure and the incidence of hospitalization for heart failure. The drug is generally well tolerated but can cause adverse [0m
[34mreactions such as hyperkalemia, hypotension, cough, and angioedema, among others. It is available in tablet form and has a bioactive metabolite called enalaprilat.[0m

[34mSOURCE: ENALAPRIL MALEATE label[0m
[34mEXTRACT_START_END: ENALAPRIL MALEATE: clinical_pharmacology: [0m[34m...[0m[34m in small increases of serum potassium.[0m
 [1m([0morchestrator-myocardial infarction-ENALAPRIL MALEATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ENALAPRIL MALEATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-ENALAPRIL MALEATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does ENALAPRIL MALEATE increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler about the effects of ENALAPRIL MALEATE."[0m[32m,[0m
[32m      [0m[32m"FDAHandler provided information on the clinical pharmacology of ENALAPRIL MALEATE, indicating its use in the treatment of hypertension, symptomatic congestive heart failure, and asymptomatic [0m
[32mleft ventricular dysfunction. It works by inhibiting the renin-angiotensin-aldosterone system, which can lower blood pressure and benefit heart failure patients."[0m[32m,[0m
[32m      [0m[32m"The FDAHandler response did not directly address the risk of myocardial infarction associated with ENALAPRIL MALEATE."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-ENALAPRIL MALEATE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-myocardial infarction-ENALAPRIL MALEATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-ENALAPRIL MALEATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-myocardial infarction-ENALAPRIL MALEATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does ENALAPRIL MALEATE increase or decrease the risk of myocardial infarction?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler about the effects of ENALAPRIL MALEATE."[0m[34m,[0m
[34m      [0m[34m"FDAHandler provided information on the clinical pharmacology of ENALAPRIL MALEATE, indicating its use in the treatment of hypertension, symptomatic congestive heart failure, and asymptomatic [0m
[34mleft ventricular dysfunction. It works by inhibiting the renin-angiotensin-aldosterone system, which can lower blood pressure and benefit heart failure patients."[0m[34m,[0m
[34m      [0m[34m"The FDAHandler response did not directly address the risk of myocardial infarction associated with ENALAPRIL MALEATE."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does ENALAPRIL MALEATE increase or decrease the risk of myocardial infarction?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler about the effects of ENALAPRIL MALEATE.[0m
[1;31m2[0m[31m. FDAHandler provided information on the clinical pharmacology of ENALAPRIL MALEATE, indicating its use in the treatment of hypertension, symptomatic congestive heart failure, and asymptomatic left [0m
[31mventricular dysfunction. It works by inhibiting the renin-angiotensin-aldosterone system, which can lower blood pressure and benefit heart failure patients.[0m
[1;31m3[0m[31m. The FDAHandler response did not directly address the risk of myocardial infarction associated with ENALAPRIL MALEATE.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-myocardial infarction-ENALAPRIL MALEATE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-myocardial infarction-ENALAPRIL MALEATE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-myocardial infarction-ENALAPRIL MALEATE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-myocardial infarction-ENALAPRIL MALEATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-ENALAPRIL MALEATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe FDAHandler provided information on the clinical pharmacology of ENALAPRIL MALEATE, indicating its use in the treatment of hypertension, symptomatic congestive heart failure, and asymptomatic left [0m
[32mventricular dysfunction. It works by inhibiting the renin-angiotensin-aldosterone system, which can lower blood pressure and benefit heart failure patients. However, the FDAHandler response did not [0m
[32mdirectly address the risk of myocardial infarction associated with ENALAPRIL MALEATE. Therefore, based on the information provided, we do not know whether ENALAPRIL MALEATE increases or decreases the [0m
[32mrisk of myocardial infarction.[0m
